Zhejiang Tianyu Pharmaceutical Co., Ltd.
SZSE:300702.SZ
20.8 (CNY) • At close October 26, 2023
Overzicht | Financiële gegevens
Cijfers zijn in miljoenen (behalve de cijfers per aandeel en de ratio's) CNY.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Omzet
| 2,527.27 | 2,666.678 | 2,545.01 | 2,587.396 | 2,110.596 | 1,466.956 | 1,188.283 | 1,082.339 | 840.085 | 777.35 | 723.25 |
| Kosten van de omzet
| 1,537.222 | 1,979.137 | 1,612.2 | 1,251.009 | 926.402 | 876.268 | 739.07 | 676.998 | 563.539 | 556.778 | 522.335 |
| Brutowinst
| 990.048 | 687.542 | 932.81 | 1,336.387 | 1,184.194 | 590.688 | 449.213 | 405.34 | 276.546 | 220.571 | 200.915 |
| Brutowinstmarge
| 0.392 | 0.258 | 0.367 | 0.516 | 0.561 | 0.403 | 0.378 | 0.375 | 0.329 | 0.284 | 0.278 |
| Onderzoek- en ontwikkelingskosten
| 243.822 | 231.104 | 227.4 | 179.065 | 112.255 | 79.46 | 59.21 | 58.73 | 41.408 | 31.076 | 32.743 |
| Algemene en administratieve kosten
| 95.458 | 126.512 | 139.849 | 105.077 | 115.768 | 93.487 | 71.03 | 55.805 | 47.969 | 36.525 | 133.909 |
| Verkoop- en marketingkosten
| 97.786 | 47.426 | 32.203 | 33.345 | 43.541 | 37.475 | 27.047 | 25.534 | 23.428 | 22.004 | 17.785 |
| Verkoop-, algemene en administratieve kosten
| 193.245 | 173.939 | 172.052 | 138.422 | 159.309 | 130.962 | 98.077 | 81.339 | 71.397 | 58.529 | 151.694 |
| Overige kosten
| 1.17 | -8.67 | -21.671 | -6.869 | 7.788 | -23.179 | -1.193 | 8.227 | 4.686 | -0.411 | 18.963 |
| Bedrijfskosten
| 673.719 | 647.119 | 697.124 | 579.854 | 476.972 | 361.811 | 276.397 | 253.973 | 208.094 | 167.376 | 157.769 |
| Bedrijfsresultaat
| 70.748 | -101.834 | 240.08 | 775.745 | 688.313 | 195.754 | 119.888 | 137.787 | 55.947 | 26.55 | 20.347 |
| Bedrijfsresultaat ratio
| 0.028 | -0.038 | 0.094 | 0.3 | 0.326 | 0.133 | 0.101 | 0.127 | 0.067 | 0.034 | 0.028 |
| Totaal overige inkomsten en kosten netto
| 1.17 | -8.67 | -21.671 | -6.869 | -4.21 | -6.451 | -1.193 | 5.534 | 4.048 | 0.106 | 18.709 |
| Inkomen voor belasting
| 71.917 | -110.504 | 218.409 | 768.876 | 684.102 | 189.304 | 118.696 | 143.321 | 59.994 | 26.656 | 39.057 |
| Inkomen voor belasting ratio
| 0.028 | -0.041 | 0.086 | 0.297 | 0.324 | 0.129 | 0.1 | 0.132 | 0.071 | 0.034 | 0.054 |
| Belastingkosten
| 44.558 | 8.449 | 13.733 | 101.815 | 98.376 | 25.642 | 18.514 | 20.983 | 9.64 | 2.516 | 5.468 |
| Nettowinst
| 27.359 | -118.953 | 204.676 | 667.061 | 585.726 | 163.662 | 100.182 | 122.338 | 50.355 | 24.14 | 33.588 |
| Nettowinstmarge
| 0.011 | -0.045 | 0.08 | 0.258 | 0.278 | 0.112 | 0.084 | 0.113 | 0.06 | 0.031 | 0.046 |
| WPA (Winst Per Aandeel)
| 0.08 | -0.34 | 0.59 | 2.06 | 1.8 | 0.51 | 0.38 | 0.51 | 0.21 | 0.1 | 0.14 |
| Verwaterde WPA
| 0.08 | -0.34 | 0.59 | 2.05 | 1.79 | 0.51 | 0.38 | 0.51 | 0.21 | 0.1 | 0.14 |
| EBITDA
| 583.53 | 300.84 | 471.463 | 878.179 | 812.917 | 306.816 | 240.221 | 231.958 | 139.062 | 96.496 | 43.782 |
| EBITDA ratio
| 0.231 | 0.113 | 0.185 | 0.339 | 0.385 | 0.209 | 0.202 | 0.214 | 0.166 | 0.124 | 0.061 |